A 58-year-old woman with a 1.5 cm nodular basal cell carcinoma on the nose is deemed a poor candidate for surgical excision due to comorbidities and patient preference. Which is the preferred systemic drug for advanced or inoperable basal cell carcinoma?

Explanation

## Systemic Therapy for Advanced Basal Cell Carcinoma **Key Point:** Vismodegib is a hedgehog pathway inhibitor (Smoothened antagonist) and the FDA/EMA-approved first-line systemic agent for locally advanced or metastatic basal cell carcinoma in patients who cannot tolerate or refuse surgery. ### Hedgehog Pathway in BCC Pathogenesis Basal cell carcinoma arises from aberrant activation of the hedgehog signaling pathway, typically due to loss-of-function mutations in **PTCH1** (patched homolog 1) or gain-of-function mutations in **SMO** (smoothened). Vismodegib blocks SMO, interrupting this oncogenic cascade. ### Vismodegib: Mechanism & Efficacy - **Drug class**: Smoothened (SMO) inhibitor; oral hedgehog pathway antagonist - **Dosing**: 150 mg once daily - **Efficacy**: - Locally advanced BCC: ~60% objective response rate - Metastatic BCC: ~30–40% response rate - Median progression-free survival: 9.5 months - **Onset**: Clinical response may take 8–12 weeks ### Indications for Vismodegib 1. Locally advanced BCC (unresectable, extensive) 2. Metastatic BCC 3. Gorlin syndrome (nevoid BCC syndrome) with multiple BCCs 4. Poor surgical candidates (age, comorbidity, patient refusal) **High-Yield:** Vismodegib is the only FDA-approved systemic agent specifically for BCC; it is NOT chemotherapy but a targeted biologic. It should NOT be used as adjuvant therapy after complete surgical resection [cite:NCCN Guidelines Basal Cell Carcinoma 2023]. ### Adverse Effects & Monitoring | Adverse Effect | Frequency | Management | |---|---|---| | Muscle cramps | 70% | Stretching, electrolyte repletion | | Dysgeusia (taste loss) | 50% | Supportive; usually reversible | | Alopecia | 60% | Cosmetic; reversible on discontinuation | | Teratogenicity | Absolute | Contraindicated in pregnancy; requires contraception | | Palmoplantar keratoderma | 30% | Supportive care | **Warning:** Vismodegib is **highly teratogenic** (Category X). Pregnancy testing and strict contraception are mandatory for all patients of childbearing potential. ### Why Not Chemotherapy? - **Methotrexate**: Non-specific antimetabolite; no role in BCC monotherapy; used only in advanced cutaneous SCC or adjuvant settings - **Doxorubicin**: Anthracycline with significant cardiotoxicity; not first-line for BCC - **Cisplatin**: Platinum agent reserved for advanced SCC or metastatic disease; not indicated for BCC **Clinical Pearl:** Vismodegib resistance can emerge after 6–12 months of therapy due to SMO mutations. In such cases, sonidegib (another SMO inhibitor) may be tried, though cross-resistance is common.